Retatrutide 40 mg is the highest-strength lyophilised vial supplied by BuyRetaUK — the presentation of choice for sustained, large-scale in-vitro programmes where a single reconstitution and a single batch reference should carry the entire study.
Retatrutide 40 mg is a 40-milligram lyophilised research-peptide vial released to ≥99% HPLC-UV with mass-spectrometric identity. It is the highest-strength presentation in the BuyRetaUK ladder, chosen for sustained large-scale in-vitro programmes and the best per-milligram economics in the range.
Retatrutide 40 mg is a lyophilised vial containing 40 milligrams of Retatrutide (LY3437943), the highest routinely stocked presentation at BuyRetaUK. It is chosen for large-scale in-vitro programmes where consolidating peptide onto a single batch minimises analytical variance and a single reconstitution should feed the entire study.
For compound-level context — mechanism, receptor pharmacology and research framing — see the cornerstone What is Retatrutide? guide.
Step down to Retatrutide 30 mg when a study will not fully consume 40 mg or when freezer capacity is constrained. Both share the same release specification — the differentiator is programme scale. For a side-by-side layout of the full 10 → 40 mg ladder, use the Strengths Hub.
Every vial ships with a batch-specific COA · UK dispatch
40 mg vials carry a batch-specific Certificate of Analysis in the same structure as every other strength. Because a single 40 mg vial often carries an entire programme, verifying the batch on arrival — cross-checking the batch number against the entry in the verification library — is particularly important. Field-by-field interpretation lives in the Certificate of Analysis guide.
40 mg vials are released against the same ≥99% HPLC-UV specification with ESI-MS identity confirmation as smaller strengths — the analytical release does not vary with vial size. Full method context lives in the Retatrutide Purity reference.
A 40 mg reconstitution produces the largest aliquot inventory in the range — plan freezer space and labelling before reconstitution, and use a mapped freezer grid so no aliquot is thawed twice. Storage temperatures and freeze-thaw framework are identical to every other strength; see the Retatrutide Storage guide for the full framework.
Reverse-phase HPLC quantifies purity as a percentage of total peak area. Release specification: ≥99%.
Learn more →Certificate of AnalysisEvery batch ships with a batch-specific COA reporting identity, purity and appearance.
Learn more →Laboratory QualityIndependent third-party analysis, temperature-controlled UK storage and full batch traceability.
Learn more →Batch VerificationCross-reference the batch number printed on your vial against our live COA library.
Learn more →Storage StandardsLyophilised at 2–8°C protected from light. Reconstituted stability ~30 days at 2–8°C.
Learn more →40 mg produces the largest aliquot inventory — confirm freezer space before ordering.
Fix a diluent volume so every 40 mg vial reconstitutes to the same working concentration used across the programme.
A single 40 mg vial can carry an entire study — cross-check the batch number against the COA before reconstituting.
Prepare labels, timepoints and a mapped freezer grid before opening the vial.
40 mg is the highest available vial strength and offers the best per-milligram economics in the range. It is chosen for sustained multi-month programmes where a single reconstitution should carry the study, or where a laboratory consolidates all study peptide onto a single batch to remove inter-batch variance.
Reconstituting 40 mg in 4 mL of bacteriostatic water yields 10 mg/mL; in 8 mL yields 5 mg/mL; in 20 mL yields 2 mg/mL. The reconstitution calculator handles any target concentration.
Choose 30 mg when total programme consumption does not justify 40 mg or when freezer capacity is constrained — a 40 mg reconstitution produces the largest aliquot inventory in the range and needs corresponding cold-chain planning.
No. 40 mg vials are released against the same ≥99% HPLC-UV specification with ESI-MS identity confirmation as every other Retatrutide strength. Only the packaged mass differs; the analytical specification is identical.
Plan the aliquot count and freezer grid before reconstitution. A 40 mg reconstitution can produce 8–20 useful aliquots depending on assay dose; each aliquot is single-use to avoid repeated freeze-thaw of the working stock.
No. Every BuyRetaUK Retatrutide vial, including 40 mg, is supplied for in-vitro laboratory research only and is not intended for human or veterinary administration.
Peer-reviewed citations are added as each article is expanded. See our editorial standards for our sourcing and accuracy commitments.
The BuyRetaUK editorial team publishes laboratory-focused reference content on research peptides, analytical methods and Certificates of Analysis. All articles are written for in-vitro research contexts only.
View profile →Every editorial article is reviewed against our accuracy commitment and quality-assurance checklist before publication. Named reviewer profiles are added as our reviewer network expands.
View profile →Every article follows a documented editorial process — sourcing, scientific review, update cadence and correction policy — so researchers can rely on what we publish.
Read the full editorial standards →Educational first. Each step is optional — start wherever you are in your research.
Compound overview, receptor profile and research framing.
Triple vs dual incretin agonist — how they differ.
Triple agonist vs single GLP-1 agonist.
How to verify identity, purity and batch quality.
Every retatrutide variant with lab data.
Solvent volume and dose-per-unit calculator.
Triple vs dual incretin agonist — receptor profile and research framing.
View comparison →Side by sideTriple agonist vs single GLP-1 — class, mechanism and lab context.
View comparison →Multi-compoundAll GLP-1 / GIP / glucagon research compounds in one place.
View comparison →A laboratory overview of retatrutide (LY3437943) — a triple agonist research peptide acting on the GLP-1, GIP and glucagon receptors.
6 min read →Storage & HandlingHow to store lyophilised research peptides and reconstitute them correctly for laboratory use.
4 min read →RetatrutideBackground on retatrutide in the academic literature — receptor pharmacology, study context and analytical handling.
8 min read →Product ComparisonsSide-by-side comparison of retatrutide and tirzepatide across receptor profile, research context and analytical considerations.
5 min read →Every batch of Retatrutide ships with a third-party HPLC and mass-spec Certificate of Analysis. Browse the live COA library to verify your lot.
Long-term frozen storage (-20°C) is acceptable for lyophilised vials, but routine refrigerated storage at 2–8°C is sufficient for typical research timelines.
Read: Storage & Reconstitution →No. Retatrutide is supplied strictly for laboratory research and is not approved for human or veterinary administration.
Read: What is Retatrutide? →In published research it has been characterised as a triple agonist acting on the GLP-1, GIP and glucagon receptors.
Read: What is Retatrutide? →Lyophilised vials are stored at 2–8°C, protected from light. Once reconstituted with bacteriostatic water, store refrigerated and use within 30 days.
Read: What is Retatrutide? →
